BioCryst Pharmaceuticals, Inc. $BCRX Stock Holdings Boosted by AlphaQuest LLC

AlphaQuest LLC lifted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 36.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 85,353 shares of the biotechnology company’s stock after acquiring an additional 22,707 shares during the period. AlphaQuest LLC’s holdings in BioCryst Pharmaceuticals were worth $765,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Allianz Asset Management GmbH grew its position in shares of BioCryst Pharmaceuticals by 9.6% during the first quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company’s stock worth $103,000 after acquiring an additional 1,200 shares during the last quarter. Royal Bank of Canada lifted its holdings in BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares during the period. Wellington Management Group LLP lifted its holdings in BioCryst Pharmaceuticals by 2.6% in the first quarter. Wellington Management Group LLP now owns 91,348 shares of the biotechnology company’s stock worth $685,000 after purchasing an additional 2,291 shares during the period. Headlands Technologies LLC acquired a new stake in BioCryst Pharmaceuticals in the first quarter worth about $32,000. Finally, R Squared Ltd lifted its holdings in BioCryst Pharmaceuticals by 84.2% in the first quarter. R Squared Ltd now owns 11,670 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 5,335 shares during the period. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Up 0.1%

Shares of NASDAQ BCRX opened at $7.20 on Monday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.31. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -40.00 and a beta of 1.05. The firm has a 50-day moving average of $7.70 and a two-hundred day moving average of $8.67.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.12. The business had revenue of $163.35 million during the quarter, compared to analyst estimates of $149.59 million. During the same period in the previous year, the company posted ($0.06) earnings per share. BioCryst Pharmaceuticals’s revenue was up 49.5% compared to the same quarter last year. As a group, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, Director Theresa Heggie sold 70,000 shares of the company’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the sale, the director directly owned 65,352 shares of the company’s stock, valued at approximately $556,145.52. This represents a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 5.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on BCRX shares. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Needham & Company LLC upped their price objective on shares of BioCryst Pharmaceuticals from $17.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, October 15th. Bank of America upped their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, July 1st. Zacks Research raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Finally, Evercore ISI reaffirmed an “in-line” rating and issued a $8.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.18.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.